drugset / Trial / NCT02557074

TREg Activation in the Treatment of the PELADE (Alopecia Areata)

NCT02557074

Phase 3 Completed 44 enrolled Centre Hospitalier Universitaire de Nice
RandomizedParallel-groupDouble-blindTreatment

Summary

In a prospective pilot study the investigators showed that low doses of IL2 could be beneficial for severe AA inducing a long lasting regrowth in 4 out of the 5 patients treated. The objective of this study is to compare the long term efficacy of low doses of IL2 versus placebo in a multicenter prospective randomized double blind study.

Timeline

Start
2015-12-15
Primary completion
2019-02-02
Completion
2019-12-02

Drugs

EvaluationDrugModalityDoseRoute
Subject aldesleukin Protein / enzyme biologic 3e+06 iu Subcutaneous

Indications